The Treatment of Type I Pneumococcus Lobar Pneumonia With Specific Serum

It is now nearly ten years since Cole and his associates at the Hospital of the Rockefeller Institute for Medical Research began the use of specific antipneumococcus serum in the treatment of lobar pneumonia due to the Type I organism. In spite of the brilliant results from time to time reported from the Rockefeller Hospital, this method of treatment has not met with special favor. Indeed, during the last few years, there has developed a somewhat widespread and growing skepticism regarding the value of antipneumococcus serum in the treatment of lobar pneumonia due to this organism. Many physicians are inclined to class this method of treatment with the numerous vaunted remedies for pneumonia which have proved of little or no value, and in which medical literature abounds. The principal reasons why the Type I serum has not come into more general use are evident. The first and most important obstacle